Engineering macrophages for cancer immunotherapy and drug delivery
Macrophages play an important role in cancer development and metastasis.
Proinflammatory M1 macrophages can phagocytose tumor cells, while anti‐inflammatory M2 …
Proinflammatory M1 macrophages can phagocytose tumor cells, while anti‐inflammatory M2 …
Emerging phagocytosis checkpoints in cancer immunotherapy
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment
Z Xu, Y Chen, L Ma, Y Chen, J Liu, Y Guo, T Yu… - Molecular Therapy, 2022 - cell.com
Exosomes have a crucial role in intercellular communication and mediate interactions
between tumor cells and tumor-associated macrophages (TAMs). Exosome-encapsulated …
between tumor cells and tumor-associated macrophages (TAMs). Exosome-encapsulated …
Phagocytosis checkpoints as new targets for cancer immunotherapy
Cancer immunotherapies targeting adaptive immune checkpoints have substantially
improved patient outcomes across multiple metastatic and treatment-refractory cancer types …
improved patient outcomes across multiple metastatic and treatment-refractory cancer types …
Strategies, design, and chemistry in siRNA delivery systems
Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad
classes of diseases due to their ability to reversibly silence target genes. In August 2018, the …
classes of diseases due to their ability to reversibly silence target genes. In August 2018, the …
The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
HL Matlung, K Szilagyi, NA Barclay… - Immunological …, 2017 - Wiley Online Library
Immune checkpoint inhibitors, including those targeting CTLA‐4/B7 and the PD‐1/PD‐L1
inhibitory pathways, are now available for clinical use in cancer patients, with other …
inhibitory pathways, are now available for clinical use in cancer patients, with other …
Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
Although great success has been obtained in the clinic, the current immune checkpoint
inhibitors still face two challenging problems: low response rate and immune-related …
inhibitors still face two challenging problems: low response rate and immune-related …
[HTML][HTML] Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review
M Lecoultre, V Dutoit, PR Walker - Journal for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Tumor-associated macrophage (TAM) phagocytic activity is emerging as a new mechanism
to harness for cancer treatment. Currently, many approaches are investigated at the …
to harness for cancer treatment. Currently, many approaches are investigated at the …
The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target
AN Barclay, TK Van den Berg - Annual review of immunology, 2014 - annualreviews.org
CD47 is a broadly expressed membrane protein that interacts with the myeloid inhibitory
immunoreceptor SIRPα (also termed CD172a or SHPS-1). SIRPα is the prototypic member …
immunoreceptor SIRPα (also termed CD172a or SHPS-1). SIRPα is the prototypic member …
Nanoparticle-based immunotherapy for cancer
The design of nanovaccines capable of triggering effective antitumor immunity requires an
understanding of how the immune system senses and responds to threats, including …
understanding of how the immune system senses and responds to threats, including …